title: Use of inhibitors in the study of MAP kinases.
abstract: The mitogen-activated protein (MAP) kinases are ubiquitous intracellular signaling proteins that respond to a variety of extracellular signals and regulate most cellular functions including proliferation, apoptosis, migration, differentiation, and secretion. The four major MAP kinase family members, which include the ERK1/2, JNK, p38, and ERK5 proteins, coordinate cellular responses by phosphorylating and regulating the activity of dozens of substrate proteins involved in transcription, translation, and changes in cellular architecture. Uncontrolled activation of the MAP kinases has been implicated in the initiation and progression of a variety of cancers and inflammatory disorders. As such, the ability to manipulate the activity of MAP kinase proteins with specific pharmacological inhibitors has received much attention as research tools for understanding basic mechanisms of cellular functions and for clinical tools to treat diseases. A variety of pharmacological inhibitors have been developed to selectively block MAP kinases directly or indirectly through targeting upstream regulators. This chapter will provide an overview of some of the current inhibitors that target MAP kinase signaling pathways and provide methodology on how to use selective MAP kinase inhibitors and immunoblotting techniques to monitor and quantify phosphorylation of MAP kinase substrates.
authors.affiliation: Department of Pharmaceutical Sciences, School of Pharmacy, University of Maryland, Baltimore, MD, USA.
authors.forename: Kimberly
authors.initials: K
authors.lastname: Burkhard
authors.forename: Paul
authors.initials: P
authors.lastname: Shapiro
mesh_terms: D000818:Animals; D000906:Antibodies / Q000276:immunology; D000918:Antibody Specificity; D003720:Densitometry; D004591:Electrophoresis, Polyacrylamide Gel; D004789:Enzyme Activation / Q000187:drug effects; D057075:Enzyme Assays / Q000379:methods*; D006367:HeLa Cells; D006801:Humans; D015151:Immunoblotting; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism*; D010750:Phosphoproteins / Q000276:immunology; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D013379:Substrate Specificity
chemical_list: D000906:Antibodies; D010750:Phosphoproteins; D047428:Protein Kinase Inhibitors; D020928:Mitogen-Activated Protein Kinases
references.citation: J Pharmacol Exp Ther. 2005 Dec;315(3):971-9
references.pmid: 16002463
references.citation: Curr Opin Cell Biol. 2009 Apr;21(2):317-24
references.pmid: 19217767
references.citation: J Biol Chem. 1998 Jul 17;273(29):18623-32
references.pmid: 9660836
references.citation: Semin Oncol. 2006 Aug;33(4):369-85
references.pmid: 16890793
references.citation: Expert Opin Emerg Drugs. 2006 Nov;11(4):651-64
references.pmid: 17064224
references.citation: J Med Chem. 2002 Jul 4;45(14):2994-3008
references.pmid: 12086485
references.citation: Clin Cancer Res. 2008 Jan 15;14(2):342-6
references.pmid: 18223206
references.citation: FEBS Lett. 1995 May 8;364(2):229-33
references.pmid: 7750577
references.citation: J Med Chem. 2005 Jul 14;48(14):4586-95
references.pmid: 15999996
references.citation: Biochem Biophys Res Commun. 2008 Dec 5;377(1):120-5
references.pmid: 18834865
references.citation: Annu Rev Immunol. 2004;22:247-306
references.pmid: 15032571
references.citation: Ann Med. 2006;38(3):200-11
references.pmid: 16720434
references.citation: FEBS Lett. 2001 Jul 27;502(1-2):21-4
references.pmid: 11478941
references.citation: Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):7686-9
references.pmid: 7644477
references.citation: Biochem J. 2003 Apr 1;371(Pt 1):199-204
references.pmid: 12534346
references.citation: Curr Opin Investig Drugs. 2008 Jun;9(6):614-30
references.pmid: 18516761
references.citation: Nat Struct Biol. 2002 Apr;9(4):268-72
references.pmid: 11896401
references.citation: Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13681-6
references.pmid: 11717429
references.citation: J Oncol Pharm Pract. 2007 Dec;13(4):199-205
references.pmid: 18045779
references.citation: Adv Cancer Res. 1998;74:49-139
references.pmid: 9561267
references.citation: Chembiochem. 2005 Mar;6(3):481-90
references.pmid: 15742384
references.citation: Expert Rev Anticancer Ther. 2006 Mar;6(3):313-9
references.pmid: 16503848
references.citation: Nat Med. 1999 Jul;5(7):810-6
references.pmid: 10395327
references.citation: Biochem J. 2000 Oct 1;351(Pt 1):95-105
references.pmid: 10998351
references.citation: Semin Oncol. 2001 Oct;28(5 Suppl 16):86-93
references.pmid: 11706400
references.citation: Structure. 1998 Sep 15;6(9):1117-28
references.pmid: 9753691
references.citation: Nature. 1994 Dec 22-29;372(6508):739-46
references.pmid: 7997261